HDAC/CK2-IN-1, identified by its CAS number 2599838-15-8, is a chemical compound that functions as an inhibitor of histone deacetylases (HDACs) and casein kinase 2 (CK2). This dual inhibition is significant in the context of cancer research, as both HDACs and CK2 are implicated in various cellular processes, including cell proliferation, differentiation, and apoptosis. The compound is characterized by its ability to modulate gene expression through epigenetic mechanisms, potentially leading to altered cellular responses in tumor cells. Its structure typically includes functional groups that facilitate binding to the active sites of the target enzymes, enhancing its inhibitory effects. Additionally, HDAC/CK2-IN-1 may exhibit selectivity towards specific isoforms of HDACs and CK2, which is crucial for minimizing off-target effects and improving therapeutic efficacy. Research into this compound is ongoing, focusing on its pharmacological properties, potential side effects, and its role in combination therapies for various malignancies.

HDAC/CK2-IN-1

2599838-15-8: HDAC/CK2-IN-1, identified by its CAS number 2599838-15-8, is a chemical compound that functions as an inhibitor of histone deacetylases (HDACs) and casein kinase 2 (CK2). This dual inhibition is significant in the context of cancer research, as both HDACs and CK2 are implicated in various cellular processes, including cell proliferation, differentiation, and apoptosis. The compound is characterized by its ability to modulate gene expression through epigenetic mechanisms, potentially leading to altered cellular responses in tumor cells. Its structure typically includes functional groups that facilitate binding to the active sites of the target enzymes, enhancing its inhibitory effects. Additionally, HDAC/CK2-IN-1 may exhibit selectivity towards specific isoforms of HDACs and CK2, which is crucial for minimizing off-target effects and improving therapeutic efficacy. Research into this compound is ongoing, focusing on its pharmacological properties, potential side effects, and its role in combination therapies for various malignancies.

HDAC/CK2-IN-1 (compound 38) acts as an inhibitor of HDAC1 (IC 50 = 1.46 μM), HDAC6 (IC 50 = 0.66 μM), and CK2 (IC 50 = 3.67 μM). It demonstrates promising antiproliferative effects on various cell lines, including Jurkat, MCF-7, HCT-116, and HL-60.

CAS 2599838-15-8

HDAC/CK2-IN-1

HDAC/CK2-IN-1

Ref: TM-T88184